A cause and effect relationship between glucagon-like peptide 1 (7, 36) amide (GLP-1) and cholecystokinin (CCK) and DMI regulation has not been established in ruminants. Three randomized complete block experiments were conducted to determine the effect of feeding fat or infusing GLP-1 or CCK intravenously on DMI, nutrient digestibility, and Cr rate of passage (using Cr 2 O 3 as a marker) in wethers. A total of 18 Targhee × Hampshire wethers (36.5 ± 2.5 kg of BW) were used, and each experiment consisted of four 21-d periods (14 d for adaptation and 7 d for infusion and sampling). Wethers allotted to the control treatments served as the controls for all 3 experiments; experiments were performed simultaneously. The basal diet was 60% concentrate and 40% forage. In Exp. 1, treatments were the control (0% added fat) and addition of 4 or 6% Ca salts of palm oil fatty acids (DM basis). Treatments in Exp. ), respectively. Increases in plasma GLP-1 and CCK concentrations during hormone infusions were comparable with increases observed when increasing amounts of fat were fed. Feeding fat and infusion of GLP-1 tended (linear, P = 0.12; quadratic, P = 0.13) to decrease DMI. Infusion of CCK did not affect (P > 0.21) DMI. Retention time of Cr in the total gastrointestinal tract decreased (linear, P < 0.01) when fat was fed, but was not affected by GLP-1 or CCK infusion. In conclusion, jugular vein infusion produced similar plasma CCK and GLP-1 concentrations as observed when fat was fed. The effects of feeding fat on DMI may be partially regulated by plasma concentration of GLP-1, but are not likely due solely to changes in a single hormone concentration.
INTRODUCTION
The addition of dietary fat decreases DMI in sheep (Reynolds et al., 2006) and cattle (Relling and Reynolds, 2007) . The decrease in DMI due to feeding fat has been associated with an increase in plasma concentration of the gut hormones glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK; Relling and Reynolds, 2007; Relling et al., 2010a) . Glucagon-like peptide-1 decreased feed intake when infused in humans (Holst, 2004) or in rats (Turton et al., 1996) and has been reported to decrease small intestine motility (Spiller et al., 1984; Holst, 1997) . In nonruminants, CCK decreases feed intake (Moran, 2004) and reduces gut motility (Walsh, 1994) .
In ruminants, no data have been reported on the effects of GLP-1 infusion on DMI or gut motility. In sheep, pharmacological doses of CCK resulted in decreased DMI (Della Fera and Baile, 1979; Grovum, 1981) . Infusion of CCK also decreased gut motility (Grovum, 1981; Romański, 2004) and increased exocrine pancreas secretion (Tachibana et al., 1995) . However, the effect of a physiological CCK infusion dose that mimics the increase in CCK concentration produced by feeding fat has not been studied previously. The hypotheses tested in the current study were 1) dietary fat increases plasma concentrations of GLP-1 and CCK, decreases DMI, decreases meal size, reduces rate of digesta passage through the gut, and does not change voluntary ME intake (MEI); 2) intravenous infusion of GLP-1 decreases DMI and rate of digesta passage through the gut, does not affect meal size, and increases diet digestibility; and 3) intravenous infusion of CCK does not change DMI, decreases rate of digesta passage, increases diet digestibility, and decreases meal size.
The objective of this experiment was to determine the effect of GLP-1 and CCK on daily and postfeeding DMI, gut motility based on Cr rate of passage, and DM and nutrient digestibility compared with feeding fat to growing lambs.
MATERIALS AND METHODS
All animal procedures were approved by the Agricultural Animal Care and Use Committee of The Ohio State University following guidelines recommended in the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching (FASS, 1998) .
Animals and Diets
For 1 mo before the start of the experiment, 24 Targhee × Hampshire wethers (36.5 ± 2.5 kg of BW) were fed a pelleted control diet (Table 1) formulated to meet nutrient requirements of growing lambs according to the NRC (1985) . The wethers were grouped into 2 BW blocks and were housed in 2 pens with 12 wethers each. Daily rations were provided at 0800 h, and wethers were fed for ad libitum intake of DM (10% refusal).
Treatments and Experimental Design
Three experiments were conducted to evaluate the effects of feeding fat, intrajugular infusion of 3 dosages of CCK, or intrajugular infusion of 3 dosages of GLP-1 on DMI, nutrient digestibility, and digesta rate of passage. The experiments were conducted simultaneously so that the same animals could serve as controls for all 3 experiments. For the fat experiment (Exp. 1), the 3 treatments were 1) control (diet without supplemental fat, Table 1 ); 2) supplemental dietary fat at 4% of ration DM (control diet plus the addition of Ca-salts of palm oil; Megalac, Church and Dwight Co. Inc., Princeton, NJ); and 3) supplemental dietary fat at 6% of ration DM. For the GLP-1 experiment (Exp. 2), the 4 treatments were intravenous infusion of GLP-1 [H6795 , respectively. The lambs fed the control diet in Exp. 1 were used as the 0 CCK infusion (control). The hormone solutions were prepared using 1 L of sterile saline solution (9 g/L of NaCl; VWR International, West Chester, PA). The wethers fed the control and the fat-supplemented diets were intravenously infused with 1 L of sterile saline solution (9 g/L of NaCl). The targeted doses of the hormones infused were calculated using a single compartment, first-order kinetic hormone degradation model, based on the following equation: increase in hormone concentration × (0.693/half life).
The half life used for this equation was 5 min for GLP-1 (Perfetti and Merkel, 2000) and 1.5 min for CCK (Hoffmann et al., 1993) . The value, 0.693, is the slope of the first-order degradation. The target increase for the 0.138 and 0.103 µg·kg of BW −1 ·d −1 doses for CCK and GLP-1, respectively, were based on a previous study in which fat was fed to lactating dairy cows and CCK-8 and GLP-1 were measured (Relling and 2 CONT = control diet; 4% fat = diet with the addition of 4% of Ca salts of palm oil; 6% fat = diet with the addition of 6% of Ca salts of palm oil.
Gut peptide infusion in wethers Reynolds, 2007) . These were designated as 100% dosages; the remaining dosages were 50 or 150% of the 100% dosages. The liter of saline solution was infused at a rate of 0.725 mL/min during 23 h.
The 3 experiments were conducted with randomized complete block designs. Each of the 2 groups of 12 lambs was considered a block, and each group was used for 2 periods (sub-blocks). Because only 12 metabolism crates were available, the blocks and sub-blocks consisted of 4 consecutive 21-d periods with an interval of 2 wk between each period. The first 14 d of each period were for adaptation, and the last 7 d were for sampling and data collection. The treatments were randomly allotted to the wethers, with the restriction that in the second period of each block the wethers were not allowed to repeat their previous treatment. On d 1 of each period the wethers were housed in individual pens (1.5 × 4.9 m). At that time, wethers fed supplemented fat were adapted to their diets with incremental increases in fat concentration in the diet; 2% of ration DM fed for the first day of the adaptation period, 4% on the second day, and the total 6%, for those designated treatment animals on d 4. On d 7, the lambs were moved into metabolic crates described previously (Murphy et al., 1994b) . From d 8 to 14, the animals were adapted to all the procedures that were conducted during the sampling week (d 15 to 21), including fecal sampling and periodically removing and weighing the feed from the bunks to measure pattern of DMI within the day. On d 13, 45 h before each sampling period started, 3 wethers were selected for removal from participation during that period based on individual inconsistency of DMI while housed in the metabolism crates or a body temperature above 39.5°C. Catheters were established in a jugular vein of the remaining 9 wethers as described previously (Huntington et al., 1989) , with a slight adjustment in the length of the catheter (36 cm total length, of which 20 cm was inside the jugular vein). The infusions started at 1000 h. The bottles with sterile saline solution and those with hormones in solution were kept on ice during the infusion. The infusion line from the bottle to the animal was sterilized using an Anprolene ethylene oxide (EtO) gas sterilizer system (EW-100778-00, Cole-Parmer, Vernon Hills, IL). The connection between the bottle with the infusion and the infusion line had a sterile 25-mm syringe filter of 0.45 µm Whatman International Ltd., Florham Park, NJ) . Between the end of the infusion of each day and the start of the infusion on the next day, the infusion lines were flushed with sterile saline solution (9 g/L of NaCl) and the filters were changed.
Sampling and Analyses
Feed was offered daily at 1300 h and the refusals were removed and weighed 23 h later at 1200 h. The DM content of feed and refusal was measured by drying at 100°C for 24 h. These measures were used to determine daily DMI. Treatment effects on pattern of meal consumption were also determined. On the last day of each period, 600 g of extra feed (as-fed basis) was fed to the wethers. At 1, 2, 4, 8, and 16 h after feeding, all feed was removed from the bunk and was weighed to determine DMI during each specific period of time. After weighing, all feed was returned to the bunks except 100 g which was removed for analysis of DM. Samples of feed were taken on each day and were pooled for analysis of CP, fatty acids (FA), NDF, and ash concentration as described previously (Beckman and Weiss, 2005) . Five minutes before feeding on the third day of the sampling period, 2 g of Cr 2 O 3 was given in an intraruminal bolus delivered in a gelatin capsule via the esophagus with the aid of a balling gun. Although Cr 2 O 3 may have a passage rate somewhat independent of liquid and solid phases of digesta, it has been used previously to estimate digesta flow in diets of growing ruminants fed diets with small and uniform particle sizes (Murphy et al., 1994a) ; our objective here was to use Cr 2 O 3 as a marker to determine relative effects of experimental treatments on digesta passage and gut motility. Fecal samples were collected via the rectum at 6, 11, 18, 24, 30, 35, 42, 48, 54, 59, 66, 72, 78, 83, 90 , and 96 h after the Cr 2 O 3 dosing to determine fecal Cr concentrations over time. The estimate of Cr rate of passage was calculated from the natural logarithms of the fecal Cr concentrations over time using the line plus exponential curve fitting function of Genstat (VSN International Ltd., Hemel Hempstead, UK) as described by Aikman et al. (2008) . Parameters to describe Cr rate of passage were calculated using a multi-compartmental model (Dhanoa et al., 1985) . For the purposes of our experiment using Cr 2 O 3 and a finely ground diet, k2 was the ascending slope and k1 was the descending slope (Grovum and Williams, 1973) , although the exact nature of the pools represented by k1 and k2 is not certain. We have also assumed that transit time (TT; h) describes passage through the remaining minor pools within the digestive. Total mean retention time (TMRT; h), representing the mean retention time of Cr in the entire digestive tract, can therefore be calculated as
To measure digestibility, total fecal collection was performed daily during the last 5 d of each sampling period. Five percent of the total daily feces was collected and pooled for analysis of DM, NDF, CP, FA, and ash concentration. The total intake was compared with the fecal output to calculate apparent digestibility (Murphy et al., 1994b) . Blood samples (10 mL) were taken 6 and 8 h after feed was offered on d 1, 4, and 6 of each sampling period. Blood samples were immediately transferred into polypropylene tubes containing solutions of disodium EDTA and benzamidine HCl (1.6 mg and 4.7 mg/mL of blood, respectively) and placed on ice. After centrifugation for 25 min at 1,800 × g and 4°C, plasma was partitioned into individual polypropylene tubes for each analysis to be performed, flash-frozen using liquid N 2 within 40 min of sample collection, and stored at −80°C until analyzed. For CCK analysis only, equal volumes of plasma from the 6-and 8-h samples were composited in a tube containing 500 Kaillikrein inhibitor units of dried aprotinin (Trasylol, Bayer, Germany) per milliliter of plasma added (Benson and Reynolds, 2001) , flash frozen using liquid N 2 after each addition, and then mixed when thawed for analysis. All other assays were performed on noncomposited samples. Samples from the infusate were taken during the first sample time on d 4 to confirm that the infusate contained the correct concentration of hormones.
Hormone and Metabolite Analysis
Concentrations of insulin, GLP-1, and CCK-8 were measured using RIA as described previously (Benson and Reynolds, 2001) , and validated based on parallel displacement of labeled hormone binding by serial addition of ovine plasma samples. The intraassay CV averaged less than 12.5, 10, and 10.3% for insulin, GLP-1, and CCK-8 assays, respectively. Minimum sensitivities (90% of zero standard binding) of the insulin, GLP-1, and CCK-8 assays were 0.0027, 0.001, and 0.0006 pmol/tube, respectively. Plasma glucose concentration was measured using a colorimetric assay (#1070 Glucose Trinder, Stanbio Laboratory, Boerne, TX). Plasma NEFA concentration was measured using microtiter plates and a plate reader in a 2-reaction, enzyme-based assay (Wako Chemicals USA, Richmond, VA) as described by Johnson and Peters (1993) .
Statistical Analysis
The data from each experiment were analyzed as randomized block designs with repeated measurements in time using the MIXED procedure (SAS Institute, Cary, NC) with a model testing the random effects of wether, block, sub-block, and the fixed effect of treatment, sampling time and the treatment × sampling time interaction. There were no treatment × sampling time interactions (P > 0.15) for any variables measured. For digestibility data, a similar statistical model was used without the effect of sampling time. For insulin, GLP-1, glucose, and NEFA, the 2 plasma samples taken at 6 and 8 h postfeeding on the 3 d of sampling in each experimental period were analyzed in the laboratory individually, but the average hormone and metabolite concentrations of both were used in the statistical analysis as 1 daily value. A paired sample t-test was used to compare plasma concentration of CCK and GLP-1 when fat was fed at 4% vs. 0.138 and 0.103 µg·kg of BW −1 ·d −1 doses for CCK and GLP-1, respectively; and when fat was fed at 6% vs. 0.207 and or 0.155 µg·kg of BW −1 ·d −1 doses for CCK and GLP-1, respectively. Orthogonal polynomial contrasts were used to partition total treatment sums of squares into the following comparisons: linear and quadratic effect of fat, GLP-1, or CCK-8. Because the unequal spacing of the fat treatments (0, 4, and 6%), Proc IML of SAS was used to estimate the appropriate coefficients. Because of inherent variation in the dependent variables measured in this experiment, significance is discussed at P ≤ 0.10, and trends are discussed at P ≤ 0.15.
RESULTS

Plasma Concentration of Hormones and Metabolites
Increasing inclusion of fat in the diet did not increase plasma GLP-1 concentration but caused a linear (P = 0.02) and quadratic (P = 0.03) increase in plasma CCK concentration (Table 2 ). There were no effects of supplemental fat on plasma insulin or glucose concentration. There was a quadratic effect (P = 0.11) of feeding fat on plasma NEFA concentration.
Comparing across experiments, plasma GLP-1 and CCK concentrations during the infusion of these hormones (Tables 3 and 4, CONT = control diet; 4% = diet with the addition of 4% of Ca salts of palm oil; 6% = diet with the addition of 6% of Ca salts of palm oil. (Table 3) , but increased plasma NEFA concentration (linear P = 0.08; Table 3 ). The incremental infusion of CCK increased plasma CCK concentration (linear P = 0.07), but did not affect insulin, GLP-1, glucose, or NEFA plasma concentrations (Table 4) .
DMI, MEI, and Digestibility
Supplemental dietary fat tended to decrease DMI (linear P = 0.13), and decreased ash digestibility (linear P = 0.05; quadratic P = 0.01). Supplemental fat also tended to increase CP digestibility (linear P = 0.11), but did not affect MEI or the digestibility of DM, NDF, FA, and OM (Table 5 ). The infusion of GLP-1 resulted in a trend for decreased DMI (quadratic P = 0.13) and MEI (quadratic P = 0.13), but did not affect the digestibility of DM, NDF, CP, FA, OM, or ash (Table 6 ). Incremental infusion of CCK did not affect DMI, MEI, DM, NDF, FA, OM, or ash digestibility (Table 7) ; however, the dosage of 0.207 µg·kg of BW −1 ·d −1 of CCK decreased (quadratic P = 0.09) CP digestibility ( Table 7) .
Pattern of Intake
Feeding increasing amounts of fat decreased DMI during the first hour after feeding (linear P = 0.09) and tended to decrease DMI during the period from 8 to 16 h after feeding (linear P = 0.12; Table 8 ). There was an effect of supplemental fat on DMI for 2 to 4 h after feeding (quadratic; P = 0.01), with the least DMI for wethers fed the diet containing 6% supplemental fat. The cumulative effect of DMI over time when fat was fed followed the trend that was observed for the first hour after feeding. A linear decrease in DMI with increasing dietary fat was observed for cumulative intakes at 2, 4, 8, and 16 h after feeding (P = 0.12, 0.08, 0.04, and 0.02, respectively). Incremental infusion of GLP-1 tended to decrease meal size during the first hour after Relling et al.
feeding (linear P = 0.12; Table 9 ) and during the period of 8 to 16 h (linear P = 0.08) after feeding. There was a trend for a quadratic (P = 0.15) effect during the period between 4 to 8 h after feeding when GLP-1 was infused, due to an increase in DMI on the 0.103 µg·kg of BW −1 ·d −1 dose of GLP-1. Intake at a specific time point would be influenced by feed consumption at earlier time points and the pattern of meal consumption. As was observed for increasing dietary fat, the incremental increase in infusion of GLP-1 tended to linearly decrease cumulative DMI at 2 and 4 h after feeding (P = 0.14 and 0.10, respectively), there was an equilibration at 8 h after feeding with no treatment effect, and a trend for decreased intake at 16 h after feeding (P = 0.12). Incremental infusion of CCK affected DMI the first hour after feeding (linear and quadratic P = 0.01) with an increased intake for the 0.069 µg·kg of BW ·d −1 infusion treatment (quadratic P = 0.04). There was a trend for reduced (quadratic P = 0.11) DMI during the period of 4 to 8 h after feeding due to a decrease in DMI for the 0.069 µg·kg of BW −1 ·d −1 treatment. From 16 to 23 h after feeding, increasing infusion of CCK resulted in increased DMI (linear and quadratic P = 0.01). The increase in DMI with incremental CCK infusion was observed also for the cumulative DMI at 4 and 8 h after feeding (linear and quadratic P = 0.01), but at 2 and 16 h after feeding, the cumulative DMI was not different among CCK infusions. Table 5 . Daily DMI, ME intake (MEI), and apparent digestibility (%) in growing wethers fed a control diet or a control diet plus addition of 4 or 6% Ca salts of palm oil 3 DMD = % DM digestibility; NDFD = % NDF digestibility; CPD = % CP digestibility; FAD = % fatty acid digestibility; OMD = % OM digestibility; AshD = % ash digestibility. Table 6 . Daily DMI, ME intake (MEI), and apparent digestibility (%) in growing wethers fed a control diet and infused with 0, 0.052, 0.103, and 0.155 µg·kg of BW 3 DMD = % DM digestibility; NDFD = % NFD digestibility; CPD = % CP digestibility; FAD = % fatty acid digestibility; OMD = % OM digestibility; AshD = % ash digestibility.
Chromium Rate of Passage
Feeding increasing amounts of dietary fat decreased TMRT of Cr (linear P = 0.01; quadratic P = 0.12). The TMRT was 28.1 h for the control and 24.2 h for the 4 and 6% supplemental fat (±0.1 SEM). Incremental increases in infusion of GLP-1 or CCK did not affect Cr retention time (P ≥ 0.17; data not shown).
DISCUSSION
Plasma Concentration of Hormones and Metabolites
In the current study, increasing amounts of dietary fat increased plasma CCK concentration but did not result in a significant increase in plasma GLP-1 concentration. Compared with the control diet, 6% supplemental fat resulted in a 70% increase in plasma CCK. In a previous study, lambs fed 6% supplemental fat diets for ad libitum intake had increased plasma GLP-1 concentration (Relling et al., 2010a) . In that study, the increase in plasma GLP-1 concentration due to supplemental fat was of greater magnitude (9 pM) than when lambs were fed the fat-supplemented diet at restricted intake (3 pM; Relling et al., 2010a) , or in the present study (5 pM). In the previous study, there was greater replication, lambs were housed in pens, and they had greater DMI and ADG than the lambs housed in metabolism crates in the present study.
When a single compartment, first-order kinetic hormone degradation equation to calculate infusion doses Table 7 . Daily DMI, ME intake (MEI), and apparent digestibility (%) in growing wethers fed a control diet and infused with 0, 0.069, 0.138, and 0.207 µg·kg of BW tion of the hormones. However, this constant infusion may not mimic a pulsatile secretion pattern in response to metabolic stimuli. Likewise, the endogenous amount secreted by the wethers could not be calculated, and there could be a feedback mechanism where an increase in plasma concentration of the hormone could decrease the rate of secretion by the gut.
The constant infusion of GLP-1 produced a linear increase in plasma NEFA concentration, which was not expected based on previous results that showed GLP-1 decreases lipolysis in the adipose tissue (Martin et al., 1993) . However, this increase in NEFA concentration does not confirm that the change was due to changes in lipolysis within the adipose tissue. In general, infusion of increasing amounts of GLP-1 had little effect on hormones or metabolites other than NEFA. More research is needed to further understand the role of GLP-1 in adipose tissue metabolism. Increasing fat supplementation and constant infusion of GLP-1 and CCK did not affect plasma concentration of glucose or insulin.
DMI, MEI, and Digestibility
In previous studies in which supplemental fat was fed to ruminants, a decrease in DMI was observed (Benson and Reynolds, 2001; Reynolds et al., 2006) . However, in the current study the effects of supplemental fat on DMI were not significant.
The digestibility of DM, CP, FA, and OM was not affected by the amount and source of supplemental dietary fat used in this experiment. Similar trends were observed in lactating dairy cows for DM, OM, NDF, CP, and FA digestibility (Harvatine and Allen, 2006) . The values for apparent FA digestibility reported here are similar to those reported by Palmquist (1991) . Based on Palmquist (1991) , the true digestibility of FA would be expected to decrease with the addition of dietary fat. The quadratic response for ash digestibility in the present study was not expected; however, the decrease observed in the wethers fed 6% of Ca salts of palm oil FA may be due to an increase of Ca lost in the feces.
The infusion of GLP-1 decreased DMI compared with the control for the 0.052 µg·kg of BW −1 ·d −1 dosage, but this decrease was not as dramatic for the 0.103 and 0.155 µg·kg of BW −1 ·d −1 dosages. As discussed above, the plasma GLP-1 concentration for the 0.103 µg·kg of BW −1 ·d −1 dosage was less than would be expected. It is not known if this affected the total DMI responses observed. Because a common diet was fed for all GLP-1 infusion concentrations, MEI resulted in a similar trend as observed for DMI. This is the first study that we are aware of in ruminants where GLP-1 was infused in physiological doses and DMI was reported. In nonruminants, GLP-1 decreases feed intake (Holst, 2006 ) via a hypothalamic mechanism (Turton et al., 1996) . However, when sheep hypothalamus was cultivated in vitro in media containing GLP-1, the mRNA concentration for neuropeptides that regulate DMI did not change (Relling et al., 2010b) . Because DMI is regulated by many factors (Forbes, 1985) , the increase in GLP-1 infusion by itself may not have been enough to depress total daily DMI. In the present study, the infusion of 0.052 µg·kg of BW −1 ·d −1 of GLP-1 resulted in a greater plasma concentration than the 0.103 µg·kg of BW −1 ·d −1 dosage and DMI followed a similar pattern. From these data, we cannot confirm that the increase within physiological ranges in plasma GLP-1 concentration is what causes decreased total daily DMI, but because of the inverse association between plasma GLP-1 and DMI, it is possible that GLP-1 contributes to the regulation of DMI. This regulation may involve changes in feeding behavior and meal consumption patterns as discussed later.
In the present study, there was no effect of CCK infusion on DMI, MEI, or DM, NDF, FA, OM, and ash digestibility. In previous studies in sheep, the infusion of CCK decreased DMI when it was infused in the jugular vein (Grovum, 1981) or was intracerebrally infused (Della Fera and Baile, 1979) . Grovum (1981) . This was an acute response (10 min) after infusing CCK in fasting sheep. In that study, no differences in intake were observed for smaller doses. Using the single compartment, firstorder kinetic hormone degradation equation described for the present study, the dosages used by Grovum (1981) would be considered to be pharmacological in nature. Additionally, Grovum (1981) did not describe the active form of CCK used. It is known that feeding fat increases plasma CCK concentration in sheep (Relling et al., 2010a) . That increase was measured using a kit that binds to CCK-8 sulfate and also cross-reacts with CCK-33 sulfate. Despite the ability to measure such an increase, it does not mean that there are not other CCK forms secreted in ruminants, as occurs in humans (where the predominant CCK circulating form is CCK-33; Walsh, 1994) or in dogs (where CCK-58 is a bioactive form; Reeve et al., 2003) . It has been observed in rats that bioactive CCK-8 is synthesized in the hypothalamus (De Fanti et al., 1998) . The reason for the decrease in intake observed when CCK-8 was intracerebrally infused (Della Fera and Baile, 1979) with smaller doses than were used in the present study may be due to paracrine functions of CCK in the hypothalamus as a neuropeptide. Although the dose used by Della Fera and Baile (1979) was smaller than the one used in the present experiment, the final concentration in the ventricle was likely greater.
Because CCK is known to increase gallbladder contraction (Walsh, 1994; Romański, 2004) and to increase pancreatic secretion of digestive enzymes (Walsh, 1994; Tachibana et al., 1995) , an increase in DM, CP, and FA digestibility was hypothesized for infusion of CCK in the present study. However, no changes in DM and FA digestibility were observed. There was a quadratic effect of CCK infusion on CP digestibility, with a slight increase for the 0.069 µg·kg of BW , which was the same amount used in the middle dosage for the current experiment; however, the dosage in the current experiment was infused in 23 h, not given as a bolus. On the other hand, Romański (2004) used bolus doses that went from 0.02 to 2 µg·kg of BW −1 .
Pattern of Intake
As hypothesized, feeding increasing amounts of dietary fat reduced DMI during the first hour after feeding. The assumption, based on nonruminant literature (Moran, 2004) , was that the decrease in DMI was produced by the resultant increase in plasma CCK concentration; however, the plasma CCK concentration for the wethers fed 4% fat was greater than for the wethers fed 6% supplemental dietary fat. It is possible that the decrease in DMI observed due to increased fat consumption was regulated by GLP-1 (D'Alessio, 2008). In the time period between 2 and 4 h after feeding, the wethers fed 4% additional dietary fat had an increase in DMI resulting in greater DMI than for lambs fed the control diet during that period. This was likely a compensatory response affected by the reduced intake during the earlier periods. Cumulative intakes throughout the day showed a consistent linear decrease in response to supplemental dietary fat. During the first 4 h postfeeding, the lambs fed 6% supplemental fat had a 45% reduction in DMI compared with the control lambs. This pattern persisted up to 16 h postfeeding, although the effect of fat was not as dramatic for the later times. These data indicate that the decrease in DMI caused by feeding fat is influenced by size of individual meals and pattern of intake as well as by a daily regulation of DMI to maintain caloric intake.
When GLP-1 was infused at increasing doses, DMI during the first hour after feeding resulted in a similar trend as when fat was fed. The cumulative DMI for most of the day showed a linear decrease in cumulative DMI with increasing GLP-1 infusion. This relationship was even more pronounced if the actual plasma GLP-1 concentrations are considered. The unexplainably decreased plasma GLP-1 concentration for the 0.103 µg·kg of BW −1 ·d −1 GLP-1 infusion coincided with a greater cumulative intake pattern than was observed for the smaller and larger dosages. These responses to GLP-1 infusion and plasma concentration were nearly identical to the responses in plasma GLP-1 and decreased cumulative intake during the day observed for increased supplemental dietary fat. The largest dosage of GLP-1 infused resulted in nearly identical plasma GLP-1 as observed for wethers fed 6% supplemental fat. The decrease in cumulative DMI for the greatest GPL-1 infusion and 6% supplemental fat was very similar at each time point postfeeding. These data provide evidence that GLP-1 has a role in regulating DMI when fat is fed. When CCK was infused, the response pattern for cumulative DMI showed a different trend than the effect of fat, not only during specific time periods after feeding, but also for the cumulative DMI data. These data suggest that the increase in plasma CCK when fat was fed was coincidental and not the causative factor in decreasing DMI. From the data in the current study, it can be concluded that GLP-1 may play a more important role in regulating DMI in response to dietary fat than CCK.
Chromium Rate of Passage
The main assumption for this part of the study was that a decrease in rumen and intestine motility caused by increased plasma concentrations of GLP-1 and CCK would reduce the rate of passage of digesta and, thus, Cr. In the present study, the increase in dietary fat increased the rate of passage of Cr through the gastrointestinal tract, mainly due to an increase in rate of passage from the pool we assume represents the rumen. Based on ruminant and nonruminant data, the opposite result was expected. Feeding fat increased plasma GLP-1 and CCK concentration. In nonruminants, GLP-1 reduced gastrointestinal motility (Holst, 1997) , which would decrease the rate of passage. In ruminants, CCK infusion decreased reticulo-rumen (Grovum, 1981) and small intestine (Romański, 2004) motility. The infusion of GLP-1 in wethers used in the present study did not change the Cr rate of passage. We are not aware of any previous reports in the literature on the effect of GLP-1 on gut motility in ruminants. The lack of response to GLP-1 on Cr rate of passage in the present study could be because GLP-1 does not have that function in ruminants or that the increase in plasma GLP-1 concentration was not great enough to produce that response. The increasing infusion of CCK did not result in a significant change in Cr retention time. Romański (2004) reported CCK infusion decreased small intestine motility in sheep. It is possible that the response in the present study was not as marked as the results observed previously (Romański, 2004) because the dosages used in the present experiment were designed to maintain physiological plasma concentrations of the hormone, and the dosages used by Romański (2004) were pharmacological. Additionally, in the present study gut motility was measured indirectly by Cr rate of passage, and in the study conducted by Romański (2004) it was measured using electrodes.
In conclusion, jugular vein infusion rates based on first-order kinetics produced similar plasma CCK and GLP-1 concentrations as observed when fat was fed. Infusion of GLP-1 resulted in similar trends in intake responses as feeding fat, such as a decrease in DMI the first hour after feeding, as well as decreased cumulative DMI at 2, 4, and 16 h after feeding. These data provide evidence for a role of GLP-1 in regulating DMI when fat is fed. When CCK was infused, the response pattern for cumulative DMI differed from that observed when fat was fed. Increased plasma CCK when fat is fed may be coincidental and not the causative factor in decreasing DMI. Our results indicate that GLP-1 plays a more important role in regulating DMI in response to dietary fat than CCK. However, regulation of feed intake is complex and likely is not controlled by a single endocrine factor such as CCK or GLP-1.
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